Olema Pharmaceuticals Inc at Canaccord Genuity Growth Conference Transcript
All right. Good afternoon. Thank you for joining us at the 43rd Annual Canaccord Genuity Growth Conference. I'm Bill Maughan, one of the biotech analysts here, and it's my pleasure to host Sean Bohen, CEO of Olema Oncology. Sean, thanks for joining us.
Thank you for having us, Bill.
Of course. So just an easy one to start, can you give us a brief introduction to the company just for anybody who might not be intimately familiar with it?
Sure. Olema is a women's cancer-focused company. We're based in San Francisco. When I say San Francisco, I actually mean the city of San Francisco and Cambridge here in the Boston area. We went public in 2020 with a single clinical asset, which is our most advanced asset, which is a complete estrogen
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
